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miRNAs are key regulators of gene expression, and alterations in their expression 
levels correlate with the onset and progression of cancer. Although miRNAs have 
been proposed as biomarkers for cancer diagnosis, their application in routine clinical 
praxis is yet to come. Current quantification strategies have limitation, and there is 
a great interest in developing innovative ones. Since a few years, nanotechnology-
based approaches for miRNA quantification are emerging at fast pace but there is 
urgent need to go beyond the proof-of-concept stage. Nanotechnology will have a 
strong impact on cancer diagnosis through miRNA detection only if it is demonstrated 
that the newly developed approaches are indeed working on ‘real-world’ samples 
under standardized conditions.
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miRNA detection & quantification 
for cancer diagnosis
miRNAs constitute the major class of endog-
enous small noncoding RNAs found in all 
living organisms and play a fundamental 
role as regulators of gene expression. Mature 
miRNAs are single-stranded oligoribonucle-
otides with a typical length between 18 and 
25 nucleotides. The mechanisms by which 
miRNAs regulate gene expression have been 
investigated in many studies and extensively 
reviewed [1–4]. Each miRNA can regulate the 
expression of hundreds of genes, simultane-
ously affecting multiple cellular pathways. 
Furthermore, each mRNA can be target of 
many different miRNAs [5]. Under patho-
logical conditions such as in cancer, dysregu-
lated miRNA levels are observed [6]. How-
ever, the relationship between dysregulated 
miRNA levels and cancer is not straightfor-
ward. In particular, each type of cancer is 
characterized by alterations in the expression 
of a more or less broad panel of miRNAs [7–
9]. Thus, miRNA profiling in combination 
with current standardized diagnostic tools 
such as histopathological diagnosis is funda-
mental for the identification of the minimal, 
representative miRNA panel allowing secure 
cancer diagnosis. In general, alteration of the 
expression level of a single miRNA has not 
sufficient diagnostic power and therefore any 
miRNA detection strategy should be ame-
nable to multiplexing, in other words, the 
parallel detection/quantification of known 
multiple miRNAs.
Another important aspect of using miR-
NAs as biomarkers for cancer diagnosis con-
cerns the identification and validation of the 
most promising specimen source among tis-
sue biopsies, blood, plasma or serum and 
other body fluids. Following the discovery 
of circulating miRNAs [10,11], there has been 
an enormous interest in identifying and vali-
dating panels of circulating miRNAs related 
to the onset and progression of cancer. Cir-
culating miRNAs are stable and protected 
from RNAse activity and may allow using a 
simple blood sample for cancer diagnosis in 
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place of a more invasive biopsy [12–15]. Other body fluids 
such as saliva, urine, seminal fluid, cerebrospinal fluid, 
breast milk and even tears contain measurable amounts 
of extracellular miRNAs [16]. However, a recent criti-
cal evaluation of the literature in this field suggests that 
circulating miRNAs are still far away from becoming 
actual biomarkers of practical clinical utility [17]. Indeed, 
most of the problems seem to be related to a widespread 
lack of reproducibility among studies dealing with 
miRNA profiling and are not exclusive to circulating 
miRNAs. Specimens of different origin have largely dif-
ferent miRNA content (Table 1) [16], differently biased 
composition (cellular vs extracellular) and require dif-
ferent preparative steps prior to miRNA quantification, 
with the possibility of introducing additional bias during 
sample preparation. One major cause of irreproducibility 
between different studies is thus related to sample pro-
cessing, which includes specimen collection and storage, 
isolation of total RNA and separation/enrichment of the 
small RNA fraction when necessary [16,18–20]. A second 
relevant cause of irreproducibility relates to the lack of 
universally accepted and validated internal references for 
miRNA quantification [21,22]. This lack of consensus in 
the selection of internal standards has a profound effect 
on the observed miRNA levels determined in different 
studies with d ifferent technological platforms [23–25].
Challenges faced by miRNA quantification 
methods
Current conventional methods for miRNA detection 
and quantification are: northern blotting, quantita-
tive reverse transcription (qRT)-PCR, microarrays and 
next-generation sequencing (NGS). It is beyond the 
scope of this work to go into the details of each method 
and the interested reader is referred to two excellent 
and up-to-date review articles [32,33]. Additionally, 
bead-based technologies, such as Luminex’s xMAP® 
(TX, USA) [34] or the Firefly® particles from Firefly 
BioWorks (MA, USA) [35], as well as the nCounter® 
system from NanoString Technologies (WA, USA) [36] 
are possible alternatives for miRNA profiling. These 
hybridization-based technologies with good multi-
plexing capability (analogous to microarrays) have 
appeared on the market in the past few years. Only 
a few studies have explicitly compared their perfor-
mances with those of the more widespread approaches 
mentioned at the beginning of this section [23,37–39].
Here, we would like to stress some general concepts 
which should be kept in mind when dealing with 
miRNA quantification for diagnostic purposes. In 
particular:
•	 miRNAs constitute only a minute fraction of the 
total RNA in biological specimens;
•	 Concentrations of miRNAs may span several 
orders of magnitude;
•	 miRNA sequences may differ just in one to a few 
nucleotides;
•	 Extracted RNA samples may contain variable 
amounts of pri- and pre-miRNA, the precur-
sors of mature miRNA, potentially affecting 
quantification;
•	 Mature miRNAs are often present as iso-miRs, 
sequences with varying termini due to variations 
in precursor processing by Drosha and/or Dicer 
enzymes;
•	 A wide range of melting temperatures (T
m
) is 
observed for duplexes composed of miRNAs and 
nucleic acid probes.
These peculiar features of miRNA, pose burdens and 
limitations to any quantification strategy. An overview 
of the main advantages and limitations of the estab-
lished miRNA quantification methods is provided in 
Table 2 with the aim of supporting the reader in under-
standing the drive to develop new strategies [40,41]. In 
the following sections of this review, we will critically 
analyze the contribution of nanotechnology to this field 
in the past 2 years. Several innovative approaches based 
on the special properties of nanostructured materials 
and devices have appeared in the scientific literature [42] 
and are expected to support the widespread adoption of 
miRNA biomarkers for cancer diagnosis. One impor-
tant contribution of nanotechnology to the detection 
of miRNAs could come from the development of 
point-of-care testing, as demonstrated by the recent 
d evelopments in other field of clinical diagnostics [43].
Nanotechnology-based methods for miRNA 
quantification
Detection and quantification of miRNAs are based on 
a molecular recognition event, typically the hybrid-
ization of a miRNA strand with a nucleic acid probe 
(or a synthetic analog) via Watson–Crick base pair-
ing, which is coupled to a transduction mechanism 
resulting in a measurable signal. The main difference 
between nanotechnology-based and conventional 
methods lies in the transduction mechanism, whereby 
the peculiar physicochemical properties of nanostruc-
tured materials are essential to enhance signal read-
out. For the purpose of this review, we have grouped 
nanotechnology-based strategies into three main 
groups: methods in solution involving nanoparticu-
late materials, approaches based on nanostructured 
surfaces and approaches based on the combination of 
na noparticulate materials with solid supports.
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Strategies based on nanoparticulate materials
Several nanoparticulate materials (nanoparticles [NPs]) 
have excellent optical properties making them ideally 
suited for the development of sensing strategies. Some 
NPs are bright and stable fluorescence emitters, for 
example, silver nanoclusters (AgNCs) and quantum dots 
(QDs), and can be used either directly or in fluorescence 
resonance energy transfer strategies. Other NPs such as 
gold NPs (AuNPs) and carbonaceous NPs can be used 
as efficient fluorescence quenchers in fluorescence recov-
ery approaches. In this case, fluorescently labeled probes 
are initially ‘dark’ because of their proximity to the NP 
surface. In the presence of target miRNA, the fluoro-
phores are physically or chemically released from the 
NP and can emit fluorescence in a concentration-depen-
dent manner. Last but not least, other properties such 
as the high surface area to volume ratio or the magnetic 
properties of NPs can be exploited for miRNA sensing. 
The detection strategies based on these properties are 
tagged ‘unconventional’ in the following paragraphs to 
distinguish them from the more classical optical detec-
tion schemes. A summary of the literature discussed 
in this section can be found in Supplementary Table 1, 
while in Figure 1 a classification of the strategies accord-
ing to detection mode and chosen amplification strategy 
is shown.
AgNCs: optical detection
AgNCs produced by nucleic acid templated synthesis [44] 
are very small NPs (∼1 nm or less) composed by a few 
silver atoms displaying a wide emission range (from 
UV to the near-IR region), outstanding photostability 
and high fluorescence efficiency [45]. AgNCs have been 
used for miRNA detection since 2011 as described by 
Yang and Vosch [46]. More recently, the Yang group 
has explored different design strategies to implement 
DNA-templated fluorescent AgNCs into miRNA 
quantification [47–49]. The common features of these 
approaches are: the miRNA recognition sequence and 
the AgNC-templating sequence and parts of the same 
oligonucleotide, and miRNA recognition results in fluo-
rescence reduction in a concentration-dependent man-
ner. Although throughout these attempts the measurable 
miRNA concentrations were found in the range from 
micromolar to nanomolar and thus probably too high to 
be of general use for miRNA quantification in biological 
samples (see Table 1), the efforts from Yang and cowork-
ers contribute in understanding the factors governing 
the formation of fl uorescent DNA-templated AgNCs.
Currently, the best way to lower the limit of detec-
tion (LOD, see Box 1) using AgNCs as the fluorescence 
reporters is to implement distinct oligonucleotides as the 
miRNA recognition sequence and the AgNC-templat-
ing sequence and to include an amplification step in the 
assay strategy. Ye and co-workers exploited target-assisted 
isothermal exponential amplification combined with 
DNA-scaffolded AgNCs [55,56]. This strategy was used 
for the concomitant quantification of miR-21 and miR-
141 in cancer cell lysates with a remarkable LOD of 100 
zmol (10 fM in 10 μl target-assisted isothermal exponen-
tial amplification reaction mixture). The method devel-
oped by Dong et al. is based on three oligonucleotides, 
in other words, a hairpin probe loaded with Hg2+ ions, 
an ‘assistant’ probe and an AgNC-templating sequence, 
used in combination with a nicking endonuclease 
enzyme (Nt.BbvCI) [57]. This assay allows also an LOD 
Table 1. Estimated ranges of miRNA concentration.
Specimen  Sample size Total RNA (μg) Amount of each 
mature miRNA
Expected conc. of each 
mature miRNA† 
Cell cultures 105 cells 0.2–3.0‡ 0.3 amol to 30 fmol§ 3 fM to 3 nM
Tissues 50–100 mg >5 0.3 amol to 30 fmol¶ 3 fM to 3 nM
Serum-plasma 200–400 μl 0.05–1# 7 zmol to 3 amol†† 70 aM to 300 fM
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of approximately 100 zmol (∼1 fM in 100 μl assay mix-
ture). However, no data were reported about miRNA 
quantification in samples of biological origin. The detec-
tion strategy developed by Zhang et al. exploited another 
peculiar photophysical property of DNA-templated 
AgNCs, namely the fluorescence enhancement of DNA-
encapsulated AgNCs produced by the vicinity of a gua-
nine (G)-rich DNA sequence [58]. This phenomenon 
was coupled to a strand displacement amplification reac-
tion catalyzed by Bsu DNA polymerase. Yet, the assay 
was found to respond to miRNA concentrations only in 
the nM–μM range (an LOD of 2.5–5 pmol or 50–100 
nM in 50 μl assay volume). Ye group proposed an inter-
esting miRNA detection method in which enzymatic 
amplification is replaced by chemical amplification [59]. 
In particular, the target miRNA strands are sandwiched 
between magnetic microparticles (MMPs) and copper 
oxide (CuO) NPs, each of which decorated with DNA 
capture probes (CPs) complementary to a portion of the 
miRNA sequence. The sandwich complexes are isolated 
by application of an external magnetic field, followed by 
dissolution of the CuO NPs with diluted nitric acid to 
release Cu2+ in solution. Next, the solution is added of 
mercaptopropionic acid (MPA), which, under aerobic 
conditions, can be oxidized to the corresponding disul-
fide catalyzed by Cu2+. Finally, detection is achieved 
by adding a fixed amount of preformed, fluorescent 
DNA-templated AgNCs, whose fluorescence is strongly 
quenched with increasing concentration of MPA, but not 
of disulfide. Thus, low miRNA amounts result in high 
MPA concentration and therefore in high fluorescence 
quenching, while high miRNA amounts result in low 
residual MPA (via oxidation) and high fluorescence. Sig-
nal amplification originates by one single CuO NP been 
made of up to 105 Cu2+ ions. However, the assay is mul-
tistep, requiring the isolation of the sandwich MMP–
miRNA–CuO NP complexes. The LOD was found 
to be approximately 1 pM but no indication was given 
about the volume of the samples from which the miRNA 
is extracted in the form of a sandwich complex. The assay 
was used to quantify miR-221–5p in cancer cell lysates.
AuNPs: optical detection
AuNPs are among the most used nanomaterials for the 
development of in vitro diagnostic systems and biosen-
sors because of their specific optical properties, which 
include localized surface plasmon resonance (LSPR), 
nanomaterial surface energy transfer and surface 
enhanced Raman scattering (SERS) [41].
Degliangeli et al. reported a real-time fluorescence 
recovery strategy for miRNA quantification based on 
enzymatic processing of DNA probes immobilized 
on PEGylated AuNPs [60]. The fluorescence of FAM-
labeled DNA probes is initially quenched via nanoma-
terial surface energy transfer by the proximity to the 
gold surface. Upon hybridization with target miRNA, 
DNA:miRNA heteroduplexes are formed and become 
substrate of the enzyme duplex-specific nuclease (DSN), 
which selectively cleaves the DNA strand leaving the 
miRNA untouched resulting in target recycling ampli-
Table 2. Advantages and limitations of current miRNA quantification methods.
Method Advantages Limitations
Northern blot •	 Quantitative
•	 Direct information about miRNA size 
(iso-miR)
•	 Large amounts of RNA
•	 Low throughput
qRT-PCR •	 Quantitative
•	 Small amounts of RNA
•	 High sensitivity due to target 
amplification
•	 Medium throughput
•	 The correct choice of an internal standard for 
normalization may be problematic
•	 No possibility of discovering new miRNAs
Microarrays •	 High throughput
•	 Hundreds of miRNA sequences 
measured simultaneously
•	 Only semiquantitative information
•	 No possibility of discovering new miRNAs
•	 Lower specificity than qRT-PCR
RNA sequencing (next-generation 
sequencing)
•	 High throughput
•	 High sensitivity and specificity
•	 Can be used to discover new miRNAs
•	 High costs
•	 Laborious data analysis requiring substantial 
specific computational knowledge
•	 Absolute miRNA quantification not possible
Bead-based technologies (xMAP®: 
Luminex, Firefly® particles: Firefly 
BioWorks, and nCounter®: 
NanoString Technologies)
•	 Medium to high throughput
•	 Hybridization takes place in solution
•	 No possibility of discovering new miRNAs
•	 Low specificity for highly similar miRNAs, 
especially if the sequence variations are at the 
5´ end
•	 Limited comparative information available
qRT: Quantitative reverse transcription.
www.futuremedicine.com 73
Figure 1. Quantification strategies based on nanoparticulate materials reviewed in this work. Classification is 
according to detection mode and signal amplification strategy. 
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fication. DNA-probe hydrolysis results in fluorescence 
recovery due to the release of the fl uorophores in s olution 
(Figure 2).
The LOD for this approach is approximately 
200 amol miRNA (or ∼5 pM in 40 μl assay mixture). 
This assay was used for the quantification of miR-21 
and miR-203 in extracted total RNA samples from 
cancer cell lines. Interestingly, the authors directly 
investigated the signal amplification contribution 
generated the DSN enzyme (Evrogen, Moscow, Rus-
sia) and found that at low miRNA concentrations 
approaching the LOD (<10 pM), the extent of this 
contribution to signal generation was relatively small 
(2–4 cleaved DNA probes/RNA).
Fluorescence recovery and DNA functionalized 
AuNPs are also exploited in the strategy developed by 
the Ma group [61]. Multiple QDs (the fluorescence emit-
ters) are tethered to the surface of DNA-functionalized 
AuNPs via a DNA linker resulting in quenched fluo-
rescence. Hybridization of target miRNA triggers the 
release in solution of the QDs with concomitant fluo-
rescence recovery. The system is designed to incorporate 
nonenzymatic target recycling amplification based on 
strand displacement involving a single-stranded ‘fuel’ 
oligonucleotide, whose function is to release the target 
miRNA. The LOD was estimated to be approximately 
500 amol (or 5 pM in 100-μl assay mixture). This assay 
was used for the quantification of miR-21 in extracted 
total RNA samples but also on living cells after con-
comitant intracellular delivery of QD–AuNP constructs 
and fuel oligonucleotides mediated by the transfection 
reagent Lipofectamine® 2000.
The colorimetric strategy reported by Ye group exploits 
the DSN enzyme and AuNP aggregation as transduction 
mechanism [62]. The assay is multistep and requires in the 
first step the enzymatic reaction on sample solutions sup-
plemented by a DNA ‘probe complex’ of specific design, 
then quenching of the enzyme and finally addition of 
DNA-functionalized AuNPs for colorimetric detection. 
The LOD of this strategy is estimated approximately 
400 amol (or 20 pM in 20-μl assay mixture, instrumen-
tal detection) and was applied to the quantification of 
miR-122 in cell lysates from human cancer cell lines.
AuNPs: unconventional detection strategies
The quantification strategy reported by Lee et al. takes 
advantage of AuNPs only as carrier material for signal 
amplification [63]. In fact, the assay strategy involves 
AuNPs functionalized with barcode DNA strands com-
plementary to a portion of target miRNA and MMPs 
74 Biomark. Med. (2017) 11(1) future science group
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functionalized with DNA strands complementary to the 
rest of the miRNA sequence. In the presence of target 
miRNA, AuNPs are captured by the MMPs forming a 
sandwich complex. The complexes are isolated by the 
application of a magnetic field, denatured to release the 
barcode DNA-functionalized AuNPs followed by com-
plete chemical etching of the gold core with KCN and 
release of the barcode DNA strands in solution. Upon 
addition of complementary oligonucleotides, double-
stranded DNAs are formed and analyzed by gel electro-
phoresis on a native polyacrylamide gel. Each miRNA 
gives rise to a separate band according to the size of the 
coding DNA sequence; thus, this strategy holds the 
intrinsic possibility of multiplexing. Although detection 
of miRNA is greatly enhanced because each AuNP car-
ries approximately 1500 barcode DNA strands and just 
1 miRNA molecule is sufficient for the immobilization 
of 1 AuNP, quantification is complicated by a nonlin-
ear response to miRNA concentration. An additional 
c oncern is the use of highly toxic cyanides in the assay.
Chen et al. also employed the multivalency of DNA-
functionalized AuNPs as a mean to amplify the detec-
tion signal [64]. Their visual detection strategy is based on 
the formation of MMP–AuNP–polymer microparticle 
ternary complexes hold together by DNA complemen-
tary strands. These complexes are the final product of a 
multistep procedure whereby the amount of AuNPs, and 
thus of sandwich complexes, reflects the initial amount of 
target miRNA. Upon application of a magnetic field in 
the detection step, the complexes are removed from the 
solution and the remaining turbidity (due to the excess 
of polymer microparticles) inversely correlates with the 
amount of miRNA, in other words, high turbidity indi-
cates low miRNA and vice versa. The assay was used to 
detect miR-155 on total RNA extracted from cultured 
cancer cells.
Zhou et al. developed a visual detection strategy based 
on the naked eye counting of fluorescent plaques in a Petri 
dish containing a host bacterial medium (Figure 3) [65]. 
The appearance of plaques is due to infection of the bac-
teria by an engineered T7 phage. According to the design 
strategy, the number of observed plaques should be the 
same as the number of phages and to the number of 
target miRNA. AuNPs are essential components of this 
assay. In fact, the strategy requires DNA-functionalized 
AuNPs and MMPs, and a T7 phage expressing gold-
binding peptides near the tips of the six tail fibers as well 
as enhanced green fluorescent protein or red fluorescent 
protein on the capsid. In the presence of target miRNA, 
preformed 1:1 AuNP/T7 phage constructs are assembled 
on the surface of MMP via sandwich hybridization. This 
multistep strategy, which includes a CsCl gradient cen-
trifugation to isolate the 1:1 AuNP/T7 phage constructs, 
was found to be applicable for the quantification of 
miRNA into spiked human serum samples. In all tested 
cases, the capturing efficiency was found approximately 
50%, in other words, the number of observed plaques is 
approximately half the expected number of miRNA mol-
ecules. This strategy is suitable only for counting miR-
NAs at less than fM concentrations owing to the limited 
capacity to accommodate plaques in a Petri dish.
QDs: optical detection
The miRNA quantification strategy developed by Jou 
et al. exploits DNA-functionalized semiconductor QDs 
as essential transduction element [66]. The DNA-probe 
strands immobilized on the QD surface carry a Black 
Hole Quencher® dye (BHQ-2 [Biosearch Technologies, 
Box 1. Limit of detection and limit of quantification
•	 Limit of detection (LOD): lowest amount of analyte in a sample that can be detected with a stated probability, 
although perhaps not quantified as an exact value [50]
•	 Limit of quantification (LOQ): lowest amount of analyte in a sample that can be quantitatively determined 
with a stated acceptable precision and trueness under stated experimental conditions [50]
•	 The assessment of a novel analytical method necessarily requires the estimation of the LOD and the related 
LOQ. Despite the common use and general understanding of the two terms, the appropriate estimation of 
these quantities has been controversial. However, there are reference documents describing internationally 
recognized and recommended procedures for meaningful LOD estimates [50–52]
•	 These procedures support the practitioner in correctly designing studies for LOD assessment, describe the 
assumptions, the statistical models underlying data treatment, and the interpretation of the results. A too 
often neglected recommendation is that a reliable estimate of the LOD requires repeated measurements 
on samples with relevant, low concentration of analyte and not only blank samples. In fact, for estimates 
based only on blank samples, there is no objective evidence that at low concentration the analyte will 
indeed produce a signal distinguishable from a blank (zero concentration) sample with a stated probability. 
Therefore, this approach ‘defines only the ability to measure nothing’ [53]. Furthermore, blanks and low level 
samples must be designed to account for matrix effects. The LOQ is generally derived from the LOD under 
given statistical assumptions which need to be verified [54]
LOD: Limit of detection; LOQ: Limit of quantification.
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Figure 2. Target miRNA hybridizes to fluorescently 
labeled DNA probes immobilized on PEGylated gold 
nanoparticles. The DNA strands of the heteroduplexes 
are selectively hydrolyzed by DSN generating a 
fluorescence signal due to release of the fluorophores. 
The signal is amplified via recycling of the intact miRNA 
target. 
DSN: Duplex-specific nuclease. 
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CA, USA]) strongly reducing QD emission. In the pres-
ence of target miRNA, heteroduplexes are formed and 
become substrate of the DSN enzyme. The possible 
amplification factor due to miRNA recycling is however 
limited by the low number of DNA strands on each QD 
(∼8) and by the fact that each tethered BHQ-2 unit con-
tributes only partially to the quenching of the total QD 
fluorescence. Nevertheless, the lowest measured miR-141 
concentration was 1 pM (or 5 amol in 5 μl miRNA solu-
tion) but under the used experimental conditions the 
method was found to have poor selectivity. The selectiv-
ity of the method could be greatly enhanced by coupling 
a second enzymatic step after DSN digestion. In particu-
lar, only the digested probe strands obtained from miR-
141:DNA probe heteroduplexes (and not those from 
other miRNAs) can work as primers for the telomerase 
enzyme. Thus, telomerase extension functions as an 
additional discriminating event but also allows further 
amplification. In fact, telomeric chains self-assemble into 
G-quadruplexes and originate peroxidase-mimicking 
DNAzyme units upon hemin binding. Finally, addition 
of hydrogen peroxide and luminol results in a chemilu-
minescence signal used as readout for miR-141 quanti-
fication in the complete assay. This approach was used 
to measure miR-141 levels in the extracted small RNA 
fraction from the serum of prostate cancer and healthy 
patients.
Other NPs: optical detection





@Ag core–shell magnetic NPs 
for miRNA capture and DSN signal amplification 
to be detected via SERS spectroscopy [67]. Detection 
occurs in a separate step following magnetic separation 




@Ag. The presence of target 
miRNA produces an attenuation of the SERS signal 
(Figure 4).
The LOD of this strategy is excellent and cor-
responds to 15 zmol miRNA (0.3 fM in 50-μl assay 
mixture). Although this approach may allow miRNA 
quantification in samples with low miRNA content 
(e.g., body fluids; see Table 1), only quantification of 
let-7b in total RNA extracted from cultured cancer 
cells was reported.
Recent years have seen an enormous interest in the 
use of carbonaceous NPs for sensing application. Single-
stranded fluorescently labeled DNA probes can adsorb 
on the surface of graphene and graphene oxide (GO) 
resulting in efficient fluorescence quenching [68,69]. 
In the presence of complementary oligonucleotides 
(e.g., target miRNA), duplexes are formed and released 
in solution resulting in fluorescence recovery. Robert-
son et al. employed nanoscale graphene oxide (nGO) to 
develop an miRNA quantification strategy mainly focus-
ing on the discrimination of miRNA sequences with a 
single mutation [70]. Their assay includes an enzymatic 
step catalyzed by DNAse I for miRNA target recycling 
and the grafting of poly(ethylene glycol) methyl ether 
methacrylate polymers to the nGO edges to abolish the 
background and improve selectivity. Bi et al. exploited 
the use of MMP/nGO composites combined with a 
cascaded chemiluminescence resonance energy transfer 
(C-CRET) mechanism for signal detection [71]. This sys-
tem is composed of a hairpin probe whose opening, upon 
target recognition, is responsible for abolishing quench-
ing via CRET and appearance of a fluorescence signal. 
The assay is discontinuous but the system is regenerable 
and generally applicable to any miRNA sequence. The 
lowest measured miRNA concentration is 100 pM in 
150-μl hybridization mixture (15-fmol miRNA).
Other organic and metal–organic materials have 
been recently tested in miRNA detection as fluo-
rescence quenchers [72,73], although with no major 
a dvantage compared with carbonaceous NPs.
Other NPs: unconventional detection strategies
Lu and coworkers reported a very sensitive miRNA 
quantification assay which exploits the change of trans-
verse relaxation time (ΔT
2
) of water molecules as the 
physical readout [74]. The assay’s principle is as follows: 
MMPs of approximately 1-μm diameter (MM
1000
) 
and 30-nm magnetic NPs (MN
30





 conjugates using heterobifunc-
tional DNA probe strands (amino modified at 5′ end 
and biotin modified at 3′ end) as linkers. These conju-
gates display on average approximately 300 MN
30
 on the 
surface of each MM
1000
 bead. In the presence of miRNA, 
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Figure 3. Quantification of miRNAs based on the naked eye counting of fluorescent plaques in a Petri dish. The 
1:1 AuNP/T7 phage assemblies are captured on magnetic microparticles in the presence of target miRNA; removal 
of excess AuNP/T7 phage assemblies, followed by T7 phage release from AuNPs driven by treatment with a 
competing peptide; the phages are finally used to infect a host bacterial medium and their reproduction produces 
colored/fluorescent plaques. Each plaque corresponds to one phage and to one miRNA. The overall counting 
efficiency is estimated around 50%, in other words, the number of visualized plaques is approximately half of the 
number of miRNA strands in the sample. 






















Review    Fiammengo
heteroduplexes are formed and hydrolyzed by the DSN 
enzyme releasing MN
30
 in solution. As earlier noted, this 
enzyme allows signal amplification via miRNA target 
recycling. After a fixed time, the released MN
30
 can be 
efficiently separated from the much larger MM
1000
 by 
applying a 0.01-T magnetic field for 3 min. This field 
strength leaves MN
30
 well dispersed in the assay mixture 
because of their low saturation magnetization. Finally, 
the ΔT
2
 of water molecules in the supernatant contain-
ing the dispersed MN
30
 is measured using a 1.5-T nuclear 
magnetic resonance spectrometer. It was found that the 
ΔT
2
 values increase with the logarithm of miRNA con-
centration, which correlates with increasing number of 
MN
30
 in solution. The method allows a remarkable LOD 
of around 150 zmol miRNA (5 fM in 30-μl assay mix-
ture) and was applied to the quantification of miR-21 in 
total RNA extracted from cancer cell lines as well as from 
tumor tissues. Nevertheless, the sensitivity of the method 
is only moderate with ΔT
2
 varying approximately 100 ms 
for each order of magnitude of miRNA concentration. 
Despite the very good LOD of this approach, quantifi-
cation of low abundance miRNAs or quantification of 
endogenous circulating miRNAs (e.g., in serum or other 
body fluids) was not demonstrated.
Strategies based on nanostructured surfaces
Quantification strategies based on solid supports are 
attractive for practical reasons such as robustness, por-
tability and storage simplicity. Substrate nanostruc-
turation directly contributes to signal transduction, 
for example, plasmon-enhanced fluorescence (PEF), 
as well as to device miniaturization. The most recent 
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Figure 4. DNA-functionalized Fe3O4@Ag core–shell magnetic nanoparticles for miRNA quantification. Fluorescent 
dyes labeling the DNA probe strands are in the vicinity of the Ag surface and produce a SERS signal. In the 
presence of target miRNA, heteroduplexes are formed and the DNA strands cleaved by the DSN enzyme, 
producing the release of fluorophores and a consequent loss of SERS signal. The intact miRNA can initiate the 
cleavage of another DNA-probe strand increasing the magnitude of signal reduction. Total RNA is incubated with 
the Fe3O4@Ag NP probes (i). The NPs are then magnetically concentrated before DSN treatment (ii). The NPs must 
be washed to remove the Cy-3-DNA fragments in solution before reading out the final Raman signal (iii). 
DSN: Duplex-specific nuclease; NP: Nanoparticle; SERS: Surface enhanced Raman scattering.  
Reprinted with permission from [67] © Elsevier (2016).
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literature describing miRNA quantification based 
on nanostructured surfaces focuses on optical detec-
tion (direct or interferometric) and is summarized in 
S upplementary Table 2.
Optical detection
The Liu group described an optical detection strat-
egy made possible by the combination of PEF with 
hybridization chain reaction (HCR), an enzyme-free 
amplification strategy [75]. In particular, a plasmonic 
chip on a glass surface was fabricated by producing 
nanostructured gold islands with abundant nanogaps 
for electromagnetic field enhancement to improve 
PEF detection. The gold surface was functionalized 
with locked nucleic acid probes complementary to one 
part of the target miRNA. The adjacent part of the 
miRNA sequence is recognized by an azide-modified 
locked nucleic acid trigger probe, which is able to 
initiate HCR in the presence of two azide-modified 
DNA hairpins. Finally, the surface immobilized HCR 
product is labeled with near-IR fluorescent dyes (cya-
nine-5, Cy5) via copper-free click chemistry involving 
the azido groups. The fluorescence of the immobilized 
dyes is largely enhanced by the PEF phenomenon. The 
lowest measured concentration of miR-21 using this 
multistep approach, which includes a denaturing step 
at 95°C, was 1 fM (50 zmol in 50-μl sample volume). 
The assay was applied to the quantification of miR-
21 in extracted total RNA from cancer cell lines. The 
ability to measure very low miRNA concentration was 
further demonstrated by reducing the amount of total 
RNA in the assay to as little as that corresponding to 
only five cells. The specificity of the assay under the 
reported conditions is only moderate.
An optical sensor based on a Mach–Zehnder interfer-
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Figure 5. Schematic drawing and a photograph of the BiMW sensor. Transverse electric-polarized light is coupled in the waveguide in 
Section A. The fundamental propagation mode splits into two modes in Section B after the step junction. The sensing window of the 
device is labeled Section C. Here the miRNA probes are immobilized on the Si3N4 surface. A two-section photodetector is placed at the 
end of the waveguide in Section D. 
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reported by Liu et al. [76]. The MZI biosensor was fabri-
cated using standard micro-nanofabrication techniques 
typical of complementary metal-oxide-semiconductor 
processes. These processes enable a larger number of 
sensors to be integrated on the same chip and therefore 
this technology is ideally suited for miRNA multiplex-
ing analysis. In practice, each MZI sensor on the chip 
can be functionalized with a different DNA probe using 
a microarray spotter and the response to each miRNA 
target can be monitored simultaneously. In essence, for 
each MZI sensor, the incoming waveguide splits into two 
arms called reference arm and sensing arm, and recom-
bines again after a certain distance before the detector 
(an IR GaAs camera). The surface of the sensing arm is 
functionalized with DNA probes and is in contact with 
the sample solution. In the presence of target miRNA, 
formation of miRNA:DNA heteroduplexes determines 
a phase change (ΔΦ) between the light beam emerg-
ing from the sensing arm and the light beam emerging 
from the reference arm. Recombination of the two light 
beams produces interference and results in a measurable 
change in light intensity, which can be used to calculate 
(ΔΦ). This physical parameter was shown to vary pro-
portionally to the base 10 logarithm of miRNA concen-
tration. The lowest measurable concentration for this 
approach is quite high (∼1 nM). However, it was pos-
sible to quantify miRNA in the small RNA-enriched 
fraction extracted from urine samples.
The Lechuga group developed a nanophotonic biosen-
sor, based on interferometric bimodal nanowaveguides 
(BiMW) [77]. The essence of the BiMW device is a single 
channel waveguide interferometer able to produce the 
interference of two waveguide modes of the same polar-
ization. This configuration avoids light beam splitting 
and recombination, which are necessary in the case of 
the previous MZI sensor. The sensing window of this 
device is situated along the bimodal section of the wave-
guide. Here, the evanescent electromagnetic field associ-
ated with the light beam propagating in the waveguide 
is in contact with the external medium and is sensitive 
to the refractive index variations of the environment. 
Since the two waveguide modes are differently confined, 
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Figure 6. Quantification strategies based on the combination of surfaces with nanoparticulate materials reviewed 
in this work. Classification according to detection mode and signal amplification strategy.  
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a phase difference accumulates along the propagation 
length giving rise to an interferometric signal which cor-
relates with the amount of miRNA target binding to the 
DNA probes (Figure 5). In particular, it was found that 
the phase shift ΔΦ exponentially increases with increas-
ing Log miRNA concentration and the LOD was esti-
mated approximately 23 aM (or ∼6 amol in the 250-μl 
s ample injected over the BiMW sensor).
The possibility of measuring remarkably low 
miRNA concentration was exploited for the quanti-
fication of miR-181a directly in urine samples. Before 
loading on the sensor, the urine sample was diluted 
1:1 (or better 1:10) with a high stringency hybridiza-
tion buffer, which was developed and tested specifi-
cally in this work. Similar to the previously described 
approach, the BiMW fabrication technology is opti-
mally suited for the preparation of sensor arrays and 
thus for multiplexing. The described BiMW sensors 
are equipped with a fluidic cell with four indepen-
dent 15 μl volume ch annels, each of which addresses a 
group of four sensors.
Combination of surface strategies with 
nanoparticulate materials
The combination of nanoparticulate materials with solid 
supports is a simple and effective way to increase the sur-
face area and to improve probe presentation/accessibility 
and can be exploited for the development of strategies 
with optical or electrochemical detection. A summary 
of the literature discussed in this section is reported in 
Supplementary Table 3, while Figure 6 reports a classifi-
cation of the different strategies according to detection 
mode and chosen a mplification s trategy.
Composites based on carbonaceous NPs
GO–AuNP composites were proposed by Wang et al. 
as key elements for a detection strategy based on surface 
plasmon resonance (SPR) [78]. This strategy employs 
a gold film carrying DNA probes, whose sequence is 
complementary to a part of the target miRNA, and 
GO–AuNP composites where the AuNPs carry DNA 
probes complementary to the adjacent, remaining 
part of the miRNA. In the presence of miRNA, the 
GO–AuNP composites are immobilized on the surface 
by sandwich hybridization. The SPR signal is enhanced 
by the electronic coupling of the localized plasmon of 
AuNPs with the surface plasmon wave associated with 
the Au film. Since each GO–AuNP flake is composed 
of many AuNPs, additional amplification of the SPR 
signal is possible. The estimated LOD of this multistep 
assay was 1 fM.
A combination of reduced GO (R-GO) and AuNPs 
was exploited by Cai et al. for the development of a 
field-effect transistor (FET) based biosensor for miRNA 
detection [79]. Peptide nucleic acid probes were used as 
the recognition element immobilized on AuNPs deco-
rating the R-GO layer. Hybridization of the target 
miRNA can be followed electrically and results in a 
shift in the gate voltage at minimum conductance when 
the transfer curve for the FET device is measured. This 
multistep assay reaches an estimated LOD of 10 fM. A 
R-GO–AuNP combination was also exploited by Cheng 
et al. for their electrochemical detection strategy [80]. 
DNA probes are immobilized on an R-GO–AuNP layer 
deposited on the surface of a glassy carbon electrode. 
Their sequence is complementary to half of the target 
miRNA. The sample solution in contact with the elec-
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Figure 7. Ultrasensitive miRNA detection via square wave voltammetry. AuNP/R-GO nanocomposites are 
deposited on the surface of a glassy carbon electrode. DNA probes (capture DNA1) are then immobilized on the 
AuNPs in the composites. In a following step, target miRNA and a biotinylated DNA sequence (capture DNA2) 
are concomitantly immobilized via hybridization. Finally, streptavidinated Cd2+-doped titanium phosphate 
nanospheres (TiP-Cd2+) are recruited to the electrode surface. The fully assembled sensor is interrogated via SWV 
monitoring the peak current for Cd2+. The large amount of Cd2+ ions incorporated into the TiP nanospheres is 
responsible for signal amplification and allows this approach to reach a record low LOD. 
AuNP: Gold nanoparticle; GCE: Glassy carbon electrode; MCH: 6-Mercapto-1-hexanol; R-GO: Reduced graphene 
oxide; SWV: Square wave voltammetry.  
Reprinted with permission from [80] © American Chemical Society (2015).
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trode also contains biotin-labeled DNA reporters com-
plementary to the other half of the miRNA. In the pres-
ence of target, the three oligonucleotides hybridize and 
recruit streptavidinated Cd2+-doped titanium phosphate 
nanospheres (TiP-Cd2+) to the electrode surface. Large 
amounts of Cd2+ ions are incorporated into the TiP 





3+, which is known to bind to double-stranded 
nucleic acids, is added to enhance electron transport. 
Detection is achieved through square wave voltammetry 
monitoring the peak current for Cd2+ (Figure 7).
This multistep assay achieves a record low LOD 
of approximately 4 ymol miRNA (∼0.8 aM in 5-μL 
sample volume) and was used for the direct quantifica-
tion of miR-21 in serum of cancer patients and healthy 
individuals.
An electrochemical strategy was reported by Azimza-
deh et al. who modified the surface of a glassy car-
bon electrode with a thin layer of GO decorated with 
DNA-functionalized gold nanorods [81]. The intercalat-
ing dye, Oracet Blue, was used to reveal the formation 
of miRNA:DNA probe hybrids via differential pulse 
voltammetry (DPV), whereby the intensity of the DPV 
current increases with miRNA concentration. Analo-
gous to other electrochemical detection strategies [42], 
this assay is multistep and involves several washing steps 
which may affect reproducibility but achieves a very 
good LOD of approximately 5 zmol miRNA (∼1 fM in 
5-μl sample volume).
The combination of single-walled carbon nanotube 
(SWCNTs) and CdS (QDs) deposited on an indium 
tin oxide (ITO) transparent electrode was exploited by 
Cao et al. for the photoelectrochemical sensing of miR-
NAs [82]. In this proof-of-principle study, the authors 
showed that one-pot synthesized DNA–CdS QDs could 
be combined with carboxyl-functionalized SWCNTs 
through π–π stacking forming the photoelectrochemi-
cally active species. These composites exhibited high 
photovoltaic conversion efficiency and good stability. 
In the presence of target miRNA, heteroduplexes are 
formed and CdS QDs are released from the surface 
of SWCNTs, resulting in a m easurable photocurrent 
r eduction (Figure 8).
The signal was further amplified using DNAse I for 
target recycling. Under optimized conditions, an LOD 
of approximately 0.6 amol (∼40 fM in 15-μl hybrid-
ization mixture) was estimated for this multistep assay 





(graphitic carbon nitride)–AuNP composites on 
an ITO substrate were exploited for the photoelectro-
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Figure 8. Photoelectrochemical detection of miRNA. DNA–CdS quantum dots are adsorbed on the surface of 
single-walled carbon nanotube on a transparent indium tin oxide substrate. Irradiation at 405 nm produces a 
strong photocurrent. In the presence of target miRNA, hybridization triggers the release of DNA–CdS QDs in 
solution and a consequent reduction in the observed photocurrent upon irradiation. The release of DNA–CdS QDs 
(and thus the photocurrent reduction) can be magnified via target recycling using the enzyme DNAse I. 
ITO: Indium tin oxide; QD: Quantum dot; SWCNT: Single-walled carbon nanotube; TGA: Thioglycolic acid; Ps-po 
DNA: DNA probe with one part of the sequence based on phosphorothioate internucleotide linkages and one 
part on natural occurring phosphodiester linkages. 
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chemical detection of miRNA [83]. Probe DNAs immo-




–AuNP layer form DNA:miRNA 
heteroduplexes which are recognized by the S9.6 anti-
body, an anti-DNA:RNA antibody. Afterward, the 
immobilized antibody is recognized by a secondary anti-
body immobilized on AuNPs labeled with alkaline phos-
phatase. Alkaline phosphatase catalyzes the hydrolysis 
of ascorbic acid-2-phosphate in the detection solution to 
produce ascorbic acid which works as the electron donor. 
As a result, in the presence of target miRNA, a strong 
photocurrent is observed and its intensity increases with 
increasing amounts of miRNA. Note that this assay 
allows signal-on detection, as opposed to the signal-off 
detection of the previous strategy, but the number of 
steps necessary for biosensor preparation is increased.
AuNPs: optical detection
The Chen group reported the use of single-nanostruc-
ture spectroscopy to quantify miRNAs in extracted total 
RNA [84]. Their chip-based sensing platform is based on 
AuNP dimers linked by stem–loop DNA and anchored 
on a glass substrate. The loop sequence is complemen-
tary to the target miRNA. Upon miRNA binding, 
the AuNP dimer geometrically extends resulting in an 
energy change for the hybridized plasmon mode, detect-
able as a spectral shift of the scattered light. Single AuNP 
dimers, composed of one AuNP with 100-nm diameter 
and one 60-nm AuNP, are imaged and identified using 
an inverted microscope with a transmitted dark-field 
condenser taking advantage of their strong light scatter-
ing properties. Single AuNPs and other aggregates can 
be differentiated by analyzing the polarized scattered 
light. After identification of single dimers, the fractional 
spectral shift, defined as the wavelength change divided 
by the initial LSPR peak position (Δλ/λ), of each dimer 
is measured. Data from 25–65 dimers undergo statisti-
cal analysis to obtain the average fractional shift, which 
was found to vary linearly with the logarithm of miRNA 
concentration up to 0.1 pM. The LOD estimated for this 
strategy is approximately 0.6 amol (or ∼9 fM in 60-μl 
sample volume), and it was possible to quantify variation 
of miR-210 levels in total RNA extracted from normoxic 
versus hypoxic cells. Although this method is still rather 
laborious from the point of view of data acquisition and 
data analysis, and displays a relatively narrow working 
range, it holds good potentiality in terms of achieving 
multiplexed arrays with ultrahigh density for biomarkers 
profiling.
The strategy developed by the Ying group is also based 
on optical detection of AuNPs on a glass surface and is 
intrinsically amenable to multiplexing [85]. They fabri-
cated a microarray of hairpin CPs, the loop of which is 
complementary to the target miRNA. The DNA hairpins 
are opened up as a consequence of miRNA hybridiza-
tion exposing a ‘universal’ single-strand DNA sequence 
which can hybridize with the signaling probes on 5-nm 
diametered AuNPs. Thus AuNPs are captured on the 
surface via formation of DNA (CP):miRNA:DNA (sig-
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naling probe) sandwich complexes and imaged by dif-
ferential interference contrast (DIC) microscopy. The 
number of immobilized AuNPs visualized by DIC was 
found to be proportional to the logarithm of miRNA 
concentration. The LOD of this strategy was found to be 
0.2 amol (10 fM in 20-μl sample solution during hybrid-
ization) but increased to 2 amol when human serum was 
analyzed.
The groups of Korc and Sardar developed a plasmonic 
biosensor for the detection of miRNAs in biological 
fluids [86,87]. The sensor is based on gold nanoprisms 
attached onto a glass substrate which are functional-
ized with DNA probes. Binding of target miRNA pro-
duces a shift of the LSPR peak measured by UV–VIS 
spectroscopy. The magnitude of this shift increases lin-
early with the logarithm of miRNA concentration. The 
LOD for miR-21 in simulated samples containing 40% 
bovine plasma or 40% human plasma was approximately 
28 amol (∼35 fM in 800-μl sample solution during 
hybridization) [86]. This sensor could be used to quantify 
miR-21 and miR-10b in human plasma samples collected 
from pancreatic ductal adenocarcinoma patients. Inter-
estingly, the authors demonstrated that the sensor surface 
can be regenerated through several cycles by treatment 
with RNAse H. Some limitations of this strategy include 
the required long hybridization time (12 h), its multistep 
implementation and its relatively low sensitivity (defined 
as the slope of the Δλ
LSPR
 vs log[miRNA] curve). In a 
following report, the authors demonstrated a >400-times 
improvement in LOD (∼80 aM or ∼64 zmol considering 
a 800-μl sample volume during hybridization as in the 
previous report) by finely tuning the dimensions of the 
Au nanoprisms [87].
AuNPs: electrochemical detection
The Ding group reported an electrochemical sensor con-
stituted by self-assembled 3D DNA origami nanostruc-
tures with a tetrahedron shape anchored on to a layer 
of AuNPs deposited on a bare gold disk electrode [88]. 
The DNA tetrahedra display at their apex a stem-loop 
portion which is tagged with an electroactive ferrocene 
moiety. Upon miRNA binding, the loop is opened and 
the overall flexibility of the structure is increased allow-
ing the ferrocene groups to contact the electrode surface 
resulting in an increased electrochemical signal. Increas-
ing miRNA concentrations results in increasing peak 
currents measured by DPV. In particular, the measured 
current varies linearly with the logarithm of miRNA 
concentration (from 100 pM to 1 μM).
The strategy described by Miao et al. [89] is based on 
chronocoulometry, a classical electrochemical technique 
where the charge (coulombs) is measured as a function 
of time. In their approach, DNA probes are immobilized 
on the surface of a gold electrode. In the presence of tar-
get miRNA, heteroduplexes are formed and can be selec-
tively cleaved by the DSN enzyme resulting in amplifi-
cation via target recycling. After a fixed time (2 h), the 
electrode is rinsed and treated with DNA-functionalized 
AuNPs, whose sequence is complementary to the DNA-
probe sequence. Thus, the number of AuNPs that can 
be immobilized on the electrode surface is high for low 
miRNA concentrations, corresponding to low amounts 
of DSN-hydrolyzed probes, and low for high miRNA 
concentration. Finally, the electrode is again rinsed and 
transferred to the electrochemical cell for chronocou-
lometry measurements. The redox charge of the elec-
trode decreases linearly with increasing the logarithm 
of miRNA concentration. The LOD of this assay for 
miR-29a-3p was estimated 50 aM.
The cyclic voltammetry approach reported by the Ma 
group consists of DNA CPs immobilized on the surface 
of a gold electrode and methylene blue labeled, G-rich 
DNA detection probes immobilized on AuNPs [90]. In 
the presence of target miRNA, sandwich complexes can 
be formed resulting in the recruitment of AuNPs to the 
electrode surface. The G-rich DNA detection probes are 
designed to fold into G-quadruplexes in the presence of K+ 
ions and bind an electrochemically active Ir(III) complex. 





 monitoring the current intensity correspond-
ing to the methylene blue reduction peak as a function 
of miRNA concentration. AuNPs are essential for sig-
nal amplification because each NP carries many G-rich 
DNA detection probes which can bind the electrochemi-
cally active Ir complex. As little as 10-fM miR-21 could 
be quantified in spiked human serum samples.
Conclusion & future perspective
Quantification of miRNA expression levels is expected 
to give a major contribution to cancer diagnosis and 
prognosis in the coming years. However, there are still 
several technological and methodological aspects related 
to miRNA quantification which need to be improved. 
In general, there is still an urgent need for standardiza-
tion in every aspect of miRNA quantification including 
the discovery of relevant miRNA panels; the validation 
of the most appropriate specimen; the sampling, storage 
and specimen processing procedures (preanalytical vari-
ables); and the actual analytical and data normalization 
procedures. Some of the limitations of currently most 
used standard technologies, that means, northern blot-
ting, qRT-PCR, microarrays and NGS, derive from hav-
ing adapted standard methods developed for the quanti-
fication of other classes of nucleic acids (e.g., DNA and 
mRNA) to the analysis of miRNAs. Therefore, there is 
a great interest in developing new strategies for improv-
ing the accuracy, specificity, sensitivity and LOD of 
miRNA quantification.
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Nanotechnology can provide advanced materials and 
surfaces to successfully address this analytical problem. 
In fact, nanotechnology-based approaches already reach 
the required LOD for miRNA analysis even in samples 
with very low miRNA content and may produce suf-
ficient readout signal even without enzymatic ampli-
fication. However, many studies in this field stop at 
the proof-of-principle level, only use fully synthetic or 
spiked-in samples for technology assessment, do not use 
stringent controls for selectivity, do not assess sample 
quality and estimate LOD without considering inter-
nationally recognized and recommended procedures. 
Nanotechnology may give a substantial contribution 
to cancer diagnosis through quantification of miRNA 
expression levels, only if ‘nanotechnologists’ will criti-
cally consider all aspects of method development in 
close collaboration with biologists, clinicians and stat-
isticians. Yet, this field is currently flourishing and there 
are plenty of opportunities to develop truly innovative 
approaches for miRNA detection.
Finally, we anticipate that strategies employing 
nanoparticulate materials in solution may likely become 
actual qRT-PCR competitors, similar to what is happen-
ing with bead-based technologies, for example, xMAP 
from Luminex, the Firefly from Firefly BioWorks, or the 
nCounter system from NanoString Technologies. On 
the other hand, surface-based strategies, with or without 
the concurrent use of NPs, are better suited for multi-
plexing analysis in form of arrays. At present, there are 
no nanotechnology-based strategies allowing the discov-
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miRNA detection & quantification for cancer diagnosis
•	 miRNAs, small noncoding RNAs, play a fundamental role as regulators of gene expression. Dysregulated miRNA 
expression levels are characteristics of cancer.
•	 Each type of cancer is characterized by altered expression of a panel of miRNA members. Identification of the 
minimal, representative miRNA panel is a prerequisite for secure diagnosis.
Challenges faced by miRNA quantification methods
•	 The miRNA detection method need to be selective, sensitive and has a low limit of detection especially when 
applied to samples derived from body fluids. They should also have potential for multiplexing.
Nanotechnology-based methods for miRNA quantification
•	 Can be divided into three main groups: methods in solution involving nanoparticles (NPs), methods based on 
nanostructured surfaces and methods based on the combination of nanoparticulate materials with solid supports.
•	 Silver nanoclusters, gold nanoparticles (AuNPs), quantum dots (QDs) and carbonaceous NPs are mainly exploited 
in quantification strategies based on optical detection. AuNPs can also be used simply as multivalent material for 
amplification strategies based on mass. Magnetic NPs can work as transducing elements for strategies exploiting 
nuclear magnetic resonance measurements (ΔT2).
•	 miRNA quantification strategies based on nanostructured solid supports are currently mainly used in conjunction 
with optical readout.
•	 Carbonaceous NPs and AuNPs deposited on solid supports are used in optical as well as electrochemical 
quantification strategies.
Future perspective
•	 Nanotechnology-based approaches already reach the required limit of detection for miRNA analysis even in 
samples with very low miRNA content.
•	 Sufficient readout signal may be generated even without enzymatic amplification.
•	 Newly developed methods are not always tested on real biological samples under relevant conditions.
•	 There is still an urgent need for standardization in every aspect of miRNA quantification.
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